Literature DB >> 25384624

Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy.

Anita Bálint1, Klaudia Farkas, Pallagi-Kunstár Éva, Gabriella Terhes, Edit Urbán, Mónika Szucs, Tibor Nyári, Zsuzsanna Bata, Ferenc Nagy, Zoltán Szepes, Pál Miheller, Katalin Lorinczy, Péter László Lakatos, Barbara Lovász, Szamosi Tamás, Andrea Kulcsár, Anna Berényi, Dalma Törocsik, Tímea Daróczi, Zoltán Saródi, Tibor Wittmann, Tamás Molnár.   

Abstract

OBJECTIVE: Influenza vaccination is recommended for inflammatory bowel disease (IBD) patients on immunosuppressive therapy. The objective was to evaluate the antibody and cell-mediated immune response to the split and whole virion influenza vaccine in patients with IBD treated with anti-TNF-α and immunosuppressive therapy. PATIENTS AND METHODS: One hundred and fifty-six immunocompromised IBD patients were vaccinated. Fifty-three patients (control group) refused vaccination. Split virion vaccine and whole virion vaccine were used. Serum samples were obtained for pre- and postimmunization antibody titers to influenza vaccine (A/California/7/2009 [H1N1], A/Victoria/361/2011 [H3N2], B/Wisconsin/1/2010-like B/Hubei-Wujiagang/158/2009). Cell-mediated response was evaluated using an interferon (INF)-γ, interleukine (IL)-2 and tumor necrosis factor (TNF)-α ELISA.
RESULTS: Postimmunization titers of both influenza subtypes increased significantly after the administration of split virion vaccines compared to the controls and to those who received whole virion vaccine. The antibody titers of Influenza B also increased significantly in patients immunized with split vaccine and treated with anti-TNF-α therapy. After influenza vaccination, the level of serum IL-2 significantly decreased. No serious side effects developed occurred after influenza vaccination, and the influenza-like symptoms did not differ significantly between vaccinated versus control patients. The relapse of the disease was observed in only 10% of the patients and was more common in vaccinated than in control subjects.
CONCLUSION: Split virion vaccines seem to be more effective than whole virion vaccines. Measuring the antibody responses is worthwhile in patients treated with immunosuppressants to determine the efficacy of influenza vaccination.

Entities:  

Keywords:  anti-TNF therapy; cellular immune response; immunosuppression; inflammatory bowel diseases; influenza; vaccination

Mesh:

Substances:

Year:  2014        PMID: 25384624     DOI: 10.3109/00365521.2014.928902

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

1.  Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis.

Authors:  Douglas L Nguyen; Emily T Nguyen; Matthew L Bechtold
Journal:  Dig Dis Sci       Date:  2015-03-22       Impact factor: 3.199

Review 2.  Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease.

Authors:  Alicia C Marín; Javier P Gisbert; María Chaparro
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 3.  What Do Influenza and COVID-19 Represent for Patients With Inflammatory Bowel Disease?

Authors:  Sandra Maria Barbalho; Julia Novaes Matias; Uri Adrian Prync Flato; Joao Paulo Galletti Pilon; Piero Bitelli; Marcos Alberto Pagani Junior; Antonelly Cassio Alves de Carvalho; Jesselina Francisco Dos Santos Haber; Carlos Henrique Bertoni Reis; Ricardo de Alvares Goulart
Journal:  Gastroenterology Res       Date:  2021-02-19

Review 4.  Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.

Authors:  Jennifer L Jones; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Eric I Benchimol
Journal:  J Can Assoc Gastroenterol       Date:  2021-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.